# Kodiak Sciences Inc. > Clarifo company profile — qualitative business description generated from > the company's filings. Financial statements, charts and ratios are > available on Clarifo (https://www.clarifo.com/fi/companies/Kodiak Sciences Inc.). ## Overview Kodiak Sciences Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for retinal diseases, with programs aimed at conditions such as geographic atrophy and glaucoma. It is also building a digital health platform, VETi, that combines proprietary LiDAR sensing, AI and wearable imaging concepts to support its retina franchise and related applications. ## Products & services • ABC platform-based retinal therapeutics • Geographic atrophy (GA) duet program • Glaucoma retina duet program • VETi visual engagement wearable platform • Proprietary LiDAR sensor and imaging technologies • Preclinical/clinical development of ophthalmology assets - **Retinal disease drug candidates** (0%) — Investigational biologic therapies designed for retinal diseases such as geographic atrophy and glaucoma. - **ABC platform programs** (0%) — Drug candidates built on Kodiak's Antibody Biopolymer Conjugate platform for longer-durability ocular treatment. - **Digital health and wearable imaging** (0%) — VETi and related AI-enabled wearable headset and imaging technologies. - **Research and development services** (100%) — Internal discovery, preclinical work, clinical development and regulatory preparation. - ABC platform-based retinal therapeutics - Geographic atrophy (GA) duet program - Glaucoma retina duet program - VETi visual engagement wearable platform - Proprietary LiDAR sensor and imaging technologies - Preclinical/clinical development of ophthalmology assets ## Customers Kodiak does not currently sell commercial products and has not generated product revenue, so its direct customers are not yet established. If approved, its therapies would be used by ophthalmologists and retina specialists treating patients with chronic retinal diseases, while any digital health products could be sold to clinical, research or other end users depending on the final application. Near term, the company’s economic counterparties are primarily regulators, clinical trial sites, CROs, manufacturers and potential collaboration partners rather than paying customers. - **Retina specialists and ophthalmologists** (primary) — Would prescribe any approved retinal disease therapy for patients with GA, glaucoma or related indications. - **Patients with retinal disease** (primary) — End users of future therapies, especially patients needing durable intravitreal treatment options. - **Clinical development partners** (secondary) — CROs, trial sites and manufacturers that enable development, testing and scale-up before approval. - **Potential commercialization partners** (secondary) — Third parties that may help sell, market or distribute approved products if Kodiak outsources commercialization. - **Digital health and research users** (emerging) — Potential users of VETi or related prototype devices in imaging, identity security or cognitive science applications. - Ophthalmologists and retina specialists would prescribe future approved therapies - Patients with geographic atrophy or glaucoma are the intended end users - Clinical trial sites and CROs support development before commercialization - Potential collaborators could commercialize or co-market future assets - Research or specialty users may adopt VETi if it reaches market ## Geography Kodiak is headquartered in the United States and its disclosed business activity is centered on U.S.-based research, development and corporate operations. The company has not disclosed product revenue by geography because it has no commercial sales yet, so its geographic exposure is mainly where clinical trials, suppliers, regulators and future commercialization partners are located. As a development-stage biotech, its operating footprint is driven more by trial execution and capital markets access than by end-market sales geography. - Headquartered in the United States - No product revenue disclosed because the company is pre-commercial - Clinical development and regulatory activity are primarily U.S.-centric - Future sales geography will depend on approval and partnering strategy - Operational exposure is tied to trial sites, suppliers and collaborators ## Strategy Kodiak’s strategy is to advance its ABC platform programs in geographic atrophy and glaucoma toward IND and eventual clinical development, aiming to create longer-durability retinal therapies than current standards of care. It is also extending its technology base through VETi and related LiDAR/AI work, which could broaden the company’s platform value beyond ophthalmology. Because it lacks a commercial infrastructure, the company may also rely on partnerships or future capital raises to fund development and eventual commercialization. - **Advance ABC platform retinal programs toward IND** (short-term) — Clinical entry is the key value-creation step for a pre-commercial biotech. - **Differentiate with durability and dual mechanism of action** (medium-term) — Better efficacy and less frequent dosing could improve adoption versus current therapies. - **Develop VETi and adjacent platform applications** (medium-term) — Broadens the technology base and may create optionality beyond the core retina franchise. - **Secure funding and partnership flexibility** (short-term) — The company needs capital and may need collaborators to reach commercialization. - Advance GA and glaucoma duet programs toward IND - Differentiate with dual-mechanism, longer-durability ocular therapies - Develop VETi as a platform extension for retina and adjacent uses - Preserve optionality through collaborations or outsourced commercialization - Raise additional capital to fund R&D and regulatory progress ## Risks Kodiak is a clinical-stage company with no approved products, so its value depends on successful development, regulatory clearance and eventual commercialization of its pipeline. The company also faces substantial financing risk, because it expects ongoing losses and may need to raise capital on dilutive or restrictive terms. Competitive, operational and cybersecurity risks are material because larger biopharma companies have greater resources and the company relies on complex R&D, trial execution and protected intellectual property. - **Clinical development failure or delay** [critical] — The company is in clinical-stage development and its programs may not reach approval. - **Financing and going-concern risk** [critical] — Kodiak has recurring losses, negative operating cash flow and limited cash runway. - **Commercialization execution risk** [high] — The company has no sales or marketing infrastructure and may need third parties. - **Competitive pressure in retinal disease** [high] — Rivals may develop safer, more effective or more convenient therapies sooner. - **Cybersecurity and data protection** [medium] — Remote work and sensitive IP increase exposure to phishing, ransomware and data loss. - No approved products means revenue depends on future clinical and regulatory success - Ongoing losses and going-concern risk increase dependence on external financing - Competition from larger biopharma firms could outpace Kodiak on efficacy or timing - Commercialization would require building sales, reimbursement and distribution capabilities - Cybersecurity and remote-work exposure could compromise confidential data and operations ## Accounting Kodiak’s accounting is dominated by development-stage biotech judgments rather than revenue recognition, since it has not generated product revenue. Investors should watch R&D expense timing, stock-based compensation, collaboration or royalty financing accounting, and the valuation of any future intangible assets or impairment triggers. Going-concern disclosures and estimates around clinical and regulatory milestones can also materially affect how the company is viewed financially. - **Research and development expense recognition** — Affects quarterly operating loss and cash burn visibility - **Stock-based compensation** — Impacts operating expenses and adjusted profitability comparisons - **Future collaboration or royalty arrangements** — Could affect revenue timing, liabilities and cash flow presentation - **Going-concern assessment** — Signals financing dependence and affects risk assessment - No product revenue yet, so commercialization accounting is not currently a driver - R&D expense timing affects reported losses as programs move through development - Stock-based compensation can materially affect operating expense - Future royalty or collaboration arrangements may require complex contract accounting - Going-concern and liquidity disclosures are important due to limited cash runway --- *Last updated: 2026-04-28T20:20:32.716272+00:00*